Expected Moves

The Read: FDMT's stock has historically moved about 10%–11% leading up to and following key FDA-related clinical milestones like Phase 3 enrollment completion, showing moderate volatility but only a muted ~3% move around anticipated equity raises, with no direct FDA approval event yet to gauge typical approval-day moves.